key: cord-0895281-e37f697p
authors: Ismail, Huda; Marshall, Vincent D.; Patel, Minal; Tariq, Madiha; Mohammad, Rima A.
title: The Impact of the COVID-19 Pandemic on Medical Conditions and Medication Adherence in People with Chronic Diseases
date: 2021-11-15
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2021.11.013
sha: ee0cd01617af170f945e61440853a8ea095a139b
doc_id: 895281
cord_uid: e37f697p

Background The coronavirus disease 2019 (COVID-19) pandemic has drastically disrupted primary healthcare and pharmacy services, posing a challenge in people with chronic diseases who receive routine care. Currently, there exists limited literature on the indirect impact of the pandemic on chronic disease management, particularly related to accessibility to medications and healthcare resources. Objectives To determine the prevalence of medical and medication-related problems reported by people with chronic diseases during the pandemic. Secondary objective was to identify the barriers and contributing factors related to these medical and medication-related problems. Methods The anonymous and voluntary, web-based survey was filled out by interested adult respondents with chronic disease(s) across Michigan between 9/1/2020 and 1/1/2021. Primary outcome included self-reported medical- and medication-related problems during the pandemic. Secondary outcomes included potential risk factors for medical- and medication-related problems. Descriptive statistics was used to describe respondents’ demographics, chronic disease(s) characteristics, medication adherence, medical- and medication-related problems, and COVID-19–related factors. The multivariable Firth logistic regression was used to analyze correlations between potential risk factors associated with medical- and medication-related problems. Results 1,103 respondents completed the survey and were included in the analysis. Approximately, 51% of respondents reported an medication-related problem with 19.6% reported problems obtaining medication(s) and 31.7% reported forgetting/not taking their medication(s). The top reason for problems obtaining medication(s) was doctor’s office being closed for in-person visit(s). Additionally, of all responses, more than half reported worsening symptoms of their chronic disease(s) during the pandemic especially with psychiatric disorders (79.5%) and inflammatory bowel disease (60%). Respondents with significantly higher risk of medication-related problems included being younger, being female, and having psychiatric disorder(s), diabetes or arthritis/lupus and of medical-related problems included having multiple chronic diseases, psychiatric disorder(s) and heart failure. Conclusion Understanding the consequences of the pandemic, such as medical- and medication-related problems, in this population is critical to improving healthcare accessibility and resources through potential outpatient pharmacy services during this and future pandemics.

Background. The coronavirus disease 2019 (COVID-19) pandemic has drastically disrupted 48 primary healthcare and pharmacy services, posing a challenge in people with chronic diseases 49 who receive routine care. Currently, there exists limited literature on the indirect impact of the 50 pandemic on chronic disease management, particularly related to accessibility to medications and 51 healthcare resources. 52

Objectives. To determine the prevalence of medical and medication-related problems reported 53 by people with chronic diseases during the pandemic. Secondary objective was to identify the 54 barriers and contributing factors related to these medical and medication-related problems. 55

Methods. The anonymous and voluntary, web-based survey was filled out by interested adult 56 respondents with chronic disease(s) across Michigan between 9/1/2020 and 1/1/2021. Primary 57 outcome included self-reported medical-and medication-related problems during the pandemic. 58

Secondary outcomes included potential risk factors for medical-and medication-related 59 problems. Descriptive statistics was used to describe respondents' demographics, chronic 60 disease(s) characteristics, medication adherence, medical-and medication-related problems, and 61 COVID-19-related factors. The multivariable Firth logistic regression was used to analyze 62 correlations between potential risk factors associated with medical-and medication-related 63 problems. 64

Results. 1,103 respondents completed the survey and were included in the analysis. 65

Approximately, 51% of respondents reported an medication-related problem with 19.6% 66 reported problems obtaining medication(s) and 31.7% reported forgetting/not taking their 67 medication(s). The top reason for problems obtaining medication(s) was doctor's office being 68 closed for in-person visit(s). Additionally, of all responses, more than half reported worsening 69 J o u r n a l P r e -p r o o f  People with chronic disease reported problems getting their medications due to their 92 doctor's office being closed for in-person visit(s), their doctor's office requiring an 93 appointment prior to prescribing medication(s), shortage of their medications, and their 94 fear of getting exposed to COVID-19. 95  The COVID-19 pandemic seems to impact people with psychiatric disorders and 96 inflammatory bowel disease the most. 97  Overall, our study showed that people with chronic diseases have been impacted by the 98 COVID-19 pandemic and the results could be used to improved healthcare and outpatient 99 pharmacy accessibility and resources for this population. With more than 30 million reported cases of coronavirus disease 2019 (COVID-19) in the United 104 States (US) from March 2020 to July 2021, the COVID-19 pandemic has impacted the 105 healthcare system and been considered a public health crisis. 1 Primary healthcare and pharmacy 106 services have drastically been disrupted, 2 posing a challenge in people with chronic diseases who 107 receive routine care. 3 During the early phase of the pandemic, the number of in-person clinic 108 visits across the country decreased and telemedicine visits increased. Despite the increase in 109 telemedicine visits, the overall number of visits (in-patient and telemedicine) declined. 3 The 110 decline in the overall number of visits may put these patients' health at risk from worsening of 111 their chronic disease, especially those with psychiatric disorders. One study showed that patients 112 with increased number of missed appointments were at a greater risk of all-cause mortality, 113 especially in patients with long-term mental health conditions. In patients with long-term mental 114 health conditions, those who missed two or more appointment per year had at least an 8 fold 115

increased risk of all-cause mortality compared to those who did not miss any appointments. 4 116 Furthermore, some experts worry that patients may face obstacles obtaining their chronic 117 medications from pharmacies 3 , yet others have predicted that patients would be willing to and 118

intend on going to their local community pharmacy during the pandemic despite having multiple 119 comorbid conditions that would further increase their risk for COVID-19 infection. 5 120

There have been several studies that showed that impact of the pandemic on mental 121 health 6-10 , alcohol consumption and alcoholic liver disease 11 The aim for this study was to assess the indirect impact of the COVID-19 pandemic on people 132 with chronic diseases. The primary objective of this study was to assess the prevalence of 133 medical-and medication-related problems reported by people with chronic diseases during the 134 COVID-19 pandemic. The secondary objective was to identify the barriers and contributing 135 factors related to these medical-and medication-related problems. 136 137

Participants 139

A sample of adults across Michigan, using the University of Michigan (UM) health research 140 platform, were included. Adults who were enrolled in this platform were routed available 141 surveys based on their health history and demographic characteristics. This survey was available 142 to platform members who were aged 18 years or older and had at least one chronic disease listed 143 in their profile. Chronic disease(s) included asthma, chronic obstructive pulmonary disease 144 (COPD), arthritis, atrial fibrillation, cancer, cardiovascular disease (history of angina or heart 145 attack), chronic kidney disease, diabetes, gastroesophageal reflux disease (GERD) or peptic ulcer 146 disease, heart failure, hyperlipidemia, hypertension, inflammatory bowel disease (IBD), 147 psychiatric disorders, and stroke. Respondents who showed interested in the study were then sent 148 J o u r n a l P r e -p r o o f this survey link through the platform. One reminder was sent to all respondents that showed 149 interested in the study. The anonymous and voluntary, web-based survey was filled out by 150 respondents between September 1, 2020 and January 1, 2021. Respondents who showed interest 151 in the study and completed the survey were included in the study. We aimed for a convenience 152 sample of 1,000 respondents in our study over a 3-month time-frame due to study timeline and 153 funding constraints. The study was approved by the UM Health Sciences and Behavioral 154

Sciences Institutional Review Board. p<0.001), IBD (OR 3.80, CI 1.65-9.00; p=0.002), psychiatric disorder(s) (OR 5.12, CI 3.41-7.81; 232 p<0.001) and stroke (OR 3.13, CI 1.09-9.24; p=0.034). Over half of respondents with chronic diseases reported at least one medication-related problem 252 and more than half of all responses indicated worsening of respondents' disease symptoms 253 during the pandemic. Self-reported worsening symptoms of chronic disease was highest in 254 respondents with psychiatric disorder(s) and IBD, and risk factors associated with worsening 255 symptoms of chronic disease was highest in respondents with multiple chronic diseases, 256 psychiatric disorder(s) and heart failure. This may be due to several factors reported in our 257 study and others, which include inability to obtain medications, reduction in chronic disease 258 management services and clinic care, statewide shutdowns, and fear of COVID-19 exposure. 6,20 259 260 Respondents with psychiatric disorders appeared to be most impacted by the pandemic in regard 261 to worsening symptoms. Additionally, our study showed that over 40% of respondents with 262 psychiatric disorder(s) had trouble seeing a therapist or psychiatrist during the pandemic, further 263 worsening their symptoms. A recent study showed that there was more than a 3-fold increase in 264 the prevalence of depression symptoms during the COVID-19 pandemic compared to pre-265 pandemic. 21 Another study showed that people without baseline depression, anxiety or 266 obsessive-compulsive disorders reported a greater increase in symptoms of these psychiatric 267 disorders during the COVID-19 pandemic. 22 Additionally, a recent meta-analysis showed that 268 there was a 3-fold increase in anxiety during the COVID-19 pandemic and the prevalence of 269 anxiety was highest during the beginning and peak of the pandemic. 23 Our study also supports 270 and adds to these finding by describing the number of people with worsening psychiatric 271 disorder(s) (79.5% of respondents), identifying barriers associated with getting medications 272 (31.8% reported issue due to doctor's office was closed for in-person visits, followed by 273 canceled/rescheduled doctor's appointment [15.8%] and fear of being exposed to COVID-19 274

[15.5%]), and issues with access to therapy (43%). 275

The COVID-19 pandemic has impacted other chronic diseases as seen in our study. The second 277 largest group that experienced worsening of their chronic disease condition in our study was 278 respondents with IBD. Worsening in IBD symptoms could be due to reduction in therapeutic 279 drug monitoring, widespread cancellation of elective procedures (i.e. endoscopies) and outpatient 280 activity (i.e. infusion centers, clinic appointments). 24 Our study also reported worsening asthma 281 and COPD symptoms which was supported by the GINA and CAT scores during the pandemic 282 compared to pre-pandemic. The impact on asthma and COPD may have been due to limited 283 access to several diagnosis procedures and reduction in usual medical care. 25 To our knowledge, 284 our study is the first study that reports the impact of COVID-19 on other chronic disease(s), such 285 as asthma/COPD and IBD. 286

In addition to the impact of the pandemic on chronic diseases, our study showed that over 60% 288 of respondents who were obese/overweight reported weight gain during the pandemic with the 289 biggest contributor to weight gain was inaccessibility to gyms. Our findings are consistent with 290 recent reports that showed that 42% of adults reported undesired weight gain during the 291 pandemic with an average of 29 pounds gained. 16 This is particularly concerning in the era of 292 COVID-19 because being obese/overweight has been identified as a major risk factor for 293 hospitalization and/or COVID-related death in patients who contract the COVID-19 virus. 26,27 294

With statewide restrictions becoming less strict in more recent months and more gyms opening, 295 it is predicted to see a decrease in worsening obesity. 296

The COVID-19 pandemic has also resulted in medication-related problems in this population. 298

Our study is the first study that reported on the prevalence of medication-related problems in 299 people with chronic disease(s) during the pandemic which showed that 51.4% of respondents 300 reported at least one medication-related problem, mostly due to nonadherence to their 301 medications. Our study also showed that the risk of medication-related problems was higher in 302 younger people, women, and people with psychiatric disorder(s), diabetes or arthritis/lupus. Our 303 study findings are concerning since we know that medication nonadherence and medication-304 This study had several limitations which included all symptoms/measurements reported were 321 self-reported, and respondents' need to recall and compare their chronic disease 322 symptoms/measurements before and after the pandemic. We acknowledge that this may result in 323 recall bias. Additionally, we limited our study population to those with chronic diseases in the 324 state of Michigan and the data were not collected from a random sample. We tried to address 325 these limitations by increasing the timeline of the survey and including a large sample size in the 326 study. However, we acknowledge that the medical-and medication-related problems identified 327 in this study may not be fully generalized to the general population in the US. 328

Despite these limitations, our study conveys that medical-and medication-related problems have 329 arisen due to the pandemic. Based on our findings, interventions could be developed to target 330 high-risk patient populations identified, such as people with obesity, psychiatric disorder(s) and 331 diabetes. Clinical pharmacist involvement in these patients may address potential medication-332 related problems associated with these chronic disease(s) and address potential barriers (i.e. 333 access to care, fear of COVID-19) that could resulted in medication-related problems. The use 334 of telehealth to provide clinic services, including pharmacy services, during the pandemic, could 335 be a potential method to address medication-related problems and access to care. These are a few 336 suggested interventions that may help improve healthcare and outpatient pharmacy accessibility 337 and provide resources for people with chronic diseases during this and future pandemics. Patients who encountered problems obtaining medications* Patients who forgot and/or chose not to take medications during the pandemic* Patients with worsening of symptoms during the pandemic*

Center for Disease Control and Prevention (CDC) COVID Data Tracker

Role of telemedicine in healthcare during COVID-19 pandemic in developing 354 countries

Reduced In-Person and Increased Telehealth Outpatient 356

Visits During the COVID-19 Pandemic

Morbidity, mortality and missed appointments 359 in healthcare: a national retrospective data linkage study

Older adults' strategies for obtaining medication refills 362 in hypothetical scenarios in the face of COVID-19 risk

Depression Symptoms in US Adults Before and During the COVID-19 Pandemic

Depression, anxiety and stress during the COVID-19 pandemic: results from a New Zealand 369 cohort study on mental well-being

Association Between Mental Health Disorders 373 and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-374 analysis

COVID-19 restrictions and age-specific mental 376 health-U.S. probability-based panel evidence. Transl Psychiatry

Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-380 analysis

During the COVID-19 Pandemic in the US

Impact of COVID-19 pandemic on liver transplantation and 386 alcohol-associated liver disease in the United States

The Opioid Epidemic During the COVID-19 Pandemic

/system/files/issue-brief-increases-in-opioid-related-overdose.pdf. Accessed

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention

Concerns About the COVID-19 Pandemic From Results of a Survey Given via Social Media

Adults Before and During the COVID-19 Pandemic

Depression, anxiety and stress during the COVID-412 19 pandemic: results from a New Zealand cohort study on mental well-being

Prevalence of anxiety in the COVID-19 415 pandemic: An updated meta-analysis of community-based studies

Disease monitoring of biologic treatment in 418 IBD: early impact and future implications of COVID-19 pandemic. Frontline Gastroenterol

Impact of the COVID-19 pandemic on the 421 management of chronic non-infectious respiratory diseases

Associations between body-mass index and COVID-424 19 severity in 6·9 million people in England: a prospective, community-based

Obesity is a strong risk factor 428 for short-term mortality and adverse outcomes in Mexican patients with COVID-19: a national 429 observational study

Economic 431 impact of medication non-adherence by disease groups: a systematic review

Clinical outcomes and 434 adherence to medications measured by claims data in patients with diabetes. Diabetes Care

Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk 438 factors and associated pharmaceutical interventions. Sci Rep

Poor medication adherence in type 2 diabetes: recognizing the 441 scope of the problem and its key contributors. Patient Prefer Adherence

Delay or Avoidance of Medical Care Because 444 of COVID-19-Related Concerns -United States

Medication management and adherence during 447 the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries

Pharmacist-led interventions to improve 451 medication adherence in older adults: A meta-analysis

The impact of clinical pharmacists on drug-related problems and clinical 454 outcomes

*Values are numbers (percentages) of respondents unless otherwise indicated